All the vaccines that are available in the world to combat the effects of SARS-CoV-2, the virus that causes the COVID-19 disease, have gone through previous studies, testing phases and approval by the scientific community. which guarantees its effectiveness and safety. Regarding the effectiveness of the biological Sinovac, Portal Bogotá consulted the experts to provide greater clarity in this regard.
"The efficacy of these vaccines is proven by previous studies, in three phases, in which thousands of volunteers are vaccinated and through which biologicals are proven to be safe and effective against the COVID-19 disease, before implement a mass vaccination program for the population," explained María del Pilar Lemos, an expert in public health at Johns Hopkins University and immunology at the University of Pennsylvania School of Medicine.
According to the recent study by the New England Journal of Medicine (NEJM) it demonstrated the high effectiveness of the Sinovac vaccine, after 14 days after the second dose a 65.9% protection was reported to prevent symptoms of COVID-19, a 87.5% reduction in hospitalization, 90.3% to avoid admission to the ICU and 86.3% to prevent deaths from the virus:
What is the effectiveness of Sinovac biological?
The World Health Organization, WHO, has validated the use of the CoronaVac vaccine, manufactured by the pharmaceutical company Sinovac, based in Beijing, China, which requires two applications, and has classified it as a biological that meets the standards international standards for safety, efficacy, and manufacturing.
Therefore, the WHO clarifies to the countries that acquire the vaccine for its application that they have a guarantee of its efficacy, since Sinovac prevents a symptomatic reaction against COVID-19 in 51% of those vaccinated, while avoiding severe disease and hospitalization in 100% of individuals immunized and included in the efficacy data.
Before Sinovac was included in the list of vaccines against COVID-19, the WHO evaluated its quality, toxicity and efficacy and developed a feasibility and risk management plan. These evaluations were made by a group of regulatory experts from around the world and a Technical Advisory Group that is charged with evaluating the risks and benefits of this vaccine.
i spent probably 6 years typing on the terrible butterfly mac keyboard. my most viewed page on my personal site is… https://t.co/1VBYLI7u8R
— nix Wed Apr 14 15:09:56 +0000 2021
In the case of the Sinovac vaccine, the WHO evaluated and included inspections in the manufacturing laboratories and determined that this vaccine contains inactivated viruses, and that due to its simple handling and storage requirements, it is especially adapted to apply in areas of low resources.
The WHO recommends that Sinovac be given to people aged 18 years or older, with a gap of approximately four weeks between the first and second doses.
For his part, the Minister of Health and Social Protection, Fernando Ruíz Gómez, explained that in the last measurement made of the vaccination process, with a cutoff date of June 15, 2021, a 13% reduction in mortality from COVID-19 in adults over 80 years of age who were vaccinated with Sinovac in the country.
In Bogotá, the biological is being applied to the prioritized population in the shopping centers authorized by the District and at the points of each EPS, and since the vaccination scheme began in the capital, the Ministry of Health registered a 20% decrease in active cases with COVID-19 in people over 70 years of age, as well as a 39% reduction in people over 80 years of age during the third peak of the pandemic, which demonstrates the effectiveness of vaccines.
For her part, regarding the effectiveness of the biological inactivated virus, Sinovac, Dr. Lemos specified that this vaccine has two phases of study, through which very few adverse symptoms associated with the vaccine have been reported.
She also assures that studies have shown a reduction in mortality from the virus and a reduction in symptomatic disease of 50% in countries such as Brazil, and 91% in Turkey.
Studies in Indonesia found a 98% reduction in mortality in the population vaccinated with Sinovac and a 96% reduction in hospitalizations, while Chile reported a 67% protection against asymptomatic COVID-19 disease.